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Abstract 
The crystallization inhibitor polyvinylpyrrolidone (PVP) is commonly used as a stabilizer in the 
formation of amorphous polymer dispersions of poorly soluble pharmaceuticals. In this work we 
examine the use of a range of PVP-inspired small-molecule bis(lactams) as coformers in the 
stabilization of amorphous pharmaceutical phases creating coamorphous materials. The dimer of 
 2 
N-vinyl(caprolactam), (bisVCap, 3) was found to be an effective coamorphous-former at 
relatively low loading for carisoprodol, carbamazepine, isoniazid and ROY. 
Introduction 
 
 A major challenge in the development of new pharmaceutical products is drug 
bioavailability,
1-4
 particularly given the increasing trend towards more hydrophobic active 
pharmaceutical ingredients (APIs).
5-7
 One of the main issues affecting bioavailability is the 
solubility of the drug in water.
8
 Cocrystallization, salt formation and the use of metastable 
polymorphs have been among the methods employed to help drug solubility and dissolution 
rate.
9
 There is also increasing interest in amorphous drugs and a number of formulations 
containing amorphous APIs are now commercially available (e.g. zafirlukast, cefuroxime axetil, 
quinapril hydrochloride and nelfinavir mesylate).
10
 As the amorphous state is less 
thermodynamically stable than the crystal, amorphous materials are generally (initially) more 
water soluble and hence more bioavailable.
11
 However, both preparing and stabilizing 
amorphous materials is often challenging. Amorphous materials can be chemically less stable 
than crystalline compounds, more hygroscopic and can display a tendency to convert to 
crystalline form over time.
12
 One way to help prevent crystallization, and both chemically and 
physically stabilize molecules in an amorphous form is the addition of a second component. This 
is commonly done with a polymer
13
  with the associated disadvantage that relatively large 
molecular weight proportions are required vs. the drug quantity, often referred to as drug load. 
An alternative to the use of polymers is to use small molecules as stabilizers, creating a 
coamorphous mixture.
2, 10, 14
 Coamorphous materials are similar in concept to cocrystals,
15-19
 in 
that the second component is often complementary to the drug substance, but unlike cocrystals, 
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the goal is to disrupt favorable interactions which promote crystal formation while promoting 
drug-coamorphous-former interactions to stabilize the API on a local level. In addition to 
coamorphous phases and polymer dispersions, other approaches have been used to stabilize 
amorphous drugs including stabilization by inorganic and mesoporous materials such as silica.
20
  
One of the most common polymers used in amorphous dispersions is polyvinylpyrrolidone 
(PVP or povidone, 1).
21
 PVP is a very common formulation agent, stabilizer and viscosity 
enhancer with applications in hydrate inhibition chemistry, haircare, cosmetics, shampoos and 
drilling fluids as well as in the pharmaceutical sector. The highly polar lactam carbonyl group 
imparts excellent electron donor and hydrogen bond acceptor ability without significant 
hydrogen bond acidity. PVP is commonly used in drug formulation,
22-24
 often as a binding and 
bulking agent when making tablets or for potentially creating delayed release formulation based 
on its thermal behavior. PVP is also highly effective as a stabilizing agent for amorphous forms 
of drugs in polymer dispersions.
25-27
 Common techniques for producing API-polymer dispersions 
include microprecipitation, ball milling, spray drying and hot-melt extrusion, although the 
inherent instability of polymer-amorphous API dispersions means that there are fewer 
commercial products of this type than might be expected.
28
 Though PVP is effective at 
stabilizing the amorphous form of a range of drugs, a high loading is often required to ensure 
long-term stability typically 50 – 80 % by mass.29 Amorphous nifedipine requires a 1:4 ratio by 
mass with PVP, for example.
26
 While a high loading is not necessarily a problem for drugs with 
a small therapeutic index, drugs which require a larger dosage would either need tablets too large 
to easily swallow or multiple ‘units’ per dose, neither of which are preferable for the patient, 
with strong evidence showing the negative impact this has on the treatment of disease.
30
 
Moreover, ingestion of large amounts of PVP have been suggested to cause unpleasant side 
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effects such as diarrhoea.
31
  The other main disadvantage of PVP is that it is hygroscopic.
32
 This 
property can reduce the shelf life of the product, either by water promoted degradation of the 
drug, or because water can cause a plasticizing effect in pills, aiding molecular mobility and 
crystallization.
33
 As a result a less hygroscopic, lower loading alternative to PVP might be of 
potential utility. Small molecules such as pyrogallol,
14
 amino acids
20, 34-35
 and drug mixtures
36
 
have all previously been shown to be effective in stabilizing the amorphous form of 
pharmaceuticals by forming a coamorphous phase rather than a polymer dispersion. In the 
present work we report studies aimed at the formation of stable coamorphous API phases with 
low molecular weight dilactams 3 – 8 which are analogs of PVP (1) and the related 
polyvinylcaprolactam (PVCap, 2, derived from vinylcaprolactam, VCap). In this way we hope to 
combine the advantageous properties of polymer-amorphous dispersions with the advantageous 
features of small-molecule coamorphous phases. 
 
Scheme 1. Chemical structures of PVP and PVCap and a range of low molecular weight analogs. 
Results and Discussion 
ROY Screening 
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The highly polymorphic (5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (ROY) was 
selected for initial screening for coamorphous phase formation with small molecule analogs of 
PVP and PVCap. ROY is a precursor for the antipsychotic drug olanzapine, and is named after 
the red, orange and yellow colors of its ten solid forms.
37-38
 Due to its large number of 
polymorphs, ROY has been the focus of significant effort in expanding and controlling its solid 
form using novel methods of crystallization.
14, 39-42
 While of academic interest, the crystallinity 
of compounds such as ROY can be disadvantageous in a pharmaceutical setting in cases of low 
dissolution rate and in previous work we have shown, based on computational predictions and an 
experimental high-throughput ultrasound-based co-crystal screen, that pyrogallol is a suitable 
small-molecule coamorphous stabilizer for ROY at a 1:1 ratio based on specific interactions with 
the ROY molecule.
14
  
Compounds 3 – 8 and VCap were all ground using a mortar and pestle in a 1:1 molar 
ratio with ROY. Comparative experiments were also undertaken in the same way with PVP 
(K12) (1) and PVCap (2) in a 1:1 ratio by mass with ROY. The samples were then placed on a 
microscope slide and covered with a thin, glass cover slip and heated using a hot stage optical 
microscope until all material had melted. The samples were then removed from the hot stage and 
allowed to cool to room temperature overnight.  The cooled samples were examined under a 
microscope fitted with cross polarizing filters and assessed for crystallinity on the basis of 
birefringence. Pictures of the microscope slides and crossed polarized microscope images are 
shown in Figure 1. 
As expected, a control sample of ROY without any coformer readily crystallizes. It is 
interesting to note that under the conditions used, ROY crystallizes into three distinctive regions 
of different color suggesting that at least three different forms can be made from cooling the melt 
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in this way as previously reported by Chen et al.
43
 who observed that cooling ROY from the melt 
results in the concomitant formation of four polymorphs. The Y04 form is initially produced, and 
cross-nucleates allowing different, faster growing forms to crystallize, resulting in a mixture of 
polymorphs from the same cooling crystallization.  
   
   
   
  
a) b) 
d) 
g) 
j) 
h) 
e) 
i) 
f) 
c) 
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Figure 1. Polarized optical microscope images of ROY samples cooled overnight with an inset 
showing the entire microscope slide. a) ROY, b) ROY and PVP, c) ROY and PVCap, d) ROY 
and VCap, e) ROY and bisVCap, f) ROY and H2bisVCap, g) ROY and bisVP, h) ROY and 
H2bisVCap, i) ROY and bisHEP, j) ROY and HEPVCap. 
Under the conditions of the experiment PVP would be expected to stabilize amorphous ROY and 
prevent crystallization.
25
 Fig. 1b shows a co-melted sample of PVP and ROY which exhibits 
areas of different color suggesting that different phases may exist, though none of the phases 
show birefringence so are not crystalline and hence PVP is indeed an effective stabilizing agent 
for amorphous ROY. PVCap (which is not used as an amorphous stabilizer in the pharmaceutical 
industry) also prevents ROY crystallization and the sample remains amorphous and of a single 
phase (Fig. 1c). Interestingly the unsaturated vinylcaprolactam dimer bisVCap (3), also gives a 
coamorphous phase with ROY. In contrast, all of the other small-molecule coformers do not 
seem to be effective in preventing ROY crystallizing over time. While ROY itself crystallizes 
very quickly (within a few minutes) upon cooling, all of the small-molecule coformers slowed 
the crystallization process with crystals beginning to form within half an hour in the case of 
bisHEP, while the other coformer mixtures crystallized slowly overnight. Interestingly, 
compounds 4 – 8 resulted in different combinations of crystal habitats and amorphous regions 
suggesting that these compounds influence polymorphic outcome but are ultimately ineffective 
at coamorphous phase formation. The polymorphism of ROY is well documented
37
 and the 
crystal forms resulting from the present experiments were not further characterized. All of the 
samples were stored for a further two months at room temperature and periodically re-examined. 
No further changes were observed implying that all crystallization was complete within the first 
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24 hours and that the coamorphous phases formed by the two polymers and small molecule 
coformer bisVCap are stable for prolonged periods.  
Screening of bisVCap and bisVP with a range of drugs  
As bisVCap shows potential as an amorphous phase stabilizer for ROY, this compound along 
with the closely related bisVP was screened as a stabilizer for coamorphous phase formation 
with a range of other APIs. Twelve drugs were chosen for screening based on availability, 
thermal stability and a range of chemical functionality, Scheme 2..   
 
Scheme 2. APIs and ROY used in coamorphous screening. 
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The drug compounds shown in Scheme 2 were ground together in a 1:1 mol ratio using a mortar 
and pestle with bisVCap and with bisVP before being heated on glass slides using a hot stage 
microscope until all material had melted. Control samples without lactam coformers were also 
prepared for comparison. The slides were then allowed to cool to room temperature. The samples 
were examined using optical microscopy after storing them overnight and again two weeks after 
melting to assess their crystallinity. Optical micrographs are shown in Figure 2. Valsartan, even 
on its own, remains amorphous, consistent with the fact that the drug is marketed in a stable 
amorphous form,
44
 although crystalline forms are also known but can be hard to prepare.
45
 The 
samples prepared using bisVP (which is itself an oil) all become viscous fluids, and hence are 
better described as liquid solutions rather than coamorphous solids. From the samples prepared 
with bisVCap, mixtures with benzocaine, caffeine and metformin crystallized overnight. In 
contrast mixtures of bisVCap with carbamazepine, carisoprodol, dopamine, ethionamide, 
ibuprofen, isoniazid, mexiletine and tolfenamic acid all resulted in materials which appear 
amorphous by polarized light microscopy after 18 hours at room temperature. 
Substance No coformer bisVCap bisVP 
Benzocaine 
   
Caffeine 
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Carbamazepine 
   
Carisoprodol 
   
Dopamine 
   
Ethionamide 
   
Ibuprofen 
   
Isoniazid 
   
 11 
Metformin 
   
Mexiletine 
   
Tolfenamic 
Acid 
   
Valsartan 
   
Figure 2. Optical micrographs (with automatic intensity adjustment) showing API samples after 
cooling overnight alone (first column) and with coformers bisVCap (second column) and bisVP 
(final column). 
 
The API bisVCap combinations which appeared amorphous by polarized light microscopy were 
examined by differential scanning calorimetry (DSC). Ground 1:1 mixtures were heated past the 
melting point of the pure components (150 – 180 oC) in the DSC instrument, cooled to –85 oC 
and then subjected to a second heating cycle. The bisVCap-dopamine shows an endothermic 
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peak in the second heating cycle corresponding to melting. As no crystallization was observed in 
the hot stage microscope experiment in which the sample is heated only once, it is possible that 
recrystallization occurs during the second heating cycle and hence the coamorphous phase is 
thermally unstable. The mixtures of bisVCap with ethionamide, tolfenamic acid, mexiletine and 
ibuprofen show a number of sharp and overlapping endothermic peaks on heating, which arise 
from decomposition of the samples. Ethionamide and mexiletine both decompose soon after their 
melting points as seen in the DSC thermographs of the individual components. DSC 
thermograms of ibuprofen and tolfenamic acid on the other hand indicate that they are thermally 
stable significantly above their melting points. The decomposition of the ibuprofen/bisVCap and 
tolfenamic acid/bisVCap mixtures on heating suggests that the interaction with bisVCap 
promotes degradation of the sample implying that bisVCap is not an ideal coamorphous former 
for these compounds. Mixtures of bisVCap with carisoprodol, carbamazepine, isoniazid and 
ROY all exhibit DSC thermographs lacking features assignable to decomposition, 
recrystallization or melting endotherms in the second heating cycle following coamorphous 
phase formation, Figure . All four thermographs show an endothermic peak on initial heating 
which corresponds to the API sample melting. On cooling there are no exothermic peaks which 
would arise from recrystallization of the sample. During the second heating cycle all the 
thermographs show evidence for a glass transition consistent with the formation of amorphous 
material. The glass transitions all occur at or below room temperature, in approximately the 
region that would be expected based on the well-known ‘2/3 rule’ which suggests that a glass 
transition is expected at around 2/3 of the temperature of the melting point of the crystalline 
material in Kelvin. Hence the new amorphous materials are not ‘fragile’ glasses.46  The chemical 
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stability of the bisVCap carisoprodol coamorphous mixture was also confirmed by 
1
H NMR 
spectroscopy which confirmed that no degradation had taken place. 
 
Figure 3. Heat/cool/heat DSC thermograms of 1:1 mixtures (by mass) of bisVCap with a) 
carbamazepine, b) carisoprodol, c) isoniazid and d) ROY (exotherm up). The small exotherms on 
cooling are artefacts.  
The same heat-cool-heat cycles used in the DSC experiments were reproduced using a hot stage 
attached to a polarized light microscope for 1:1 mixtures of carisoprodol, carbamazepine, 
isoniazid and ROY with bisVCap. The results of the microscope experiments can be seen in the 
supporting information (Fig. S2 – S5) and confirm coamorphous phase formation. 
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One major problem with PVP as an amorphous stabilizer is that often a large amount is 
required for stabilization of the amorphous phase. This often leads to very large tablets or dosage 
forms which consist of multiple tablets. Thus further hot stage microscope and DSC experiments 
of bisVCap mixtures with carisoprodol, carbamazepine, isoniazid and ROY were performed with 
increasing drug:bisVCap ratios to determine the minimum ratio of coformer required to maintain 
the API in an amorphous state. 
For the microscope experiments the target drug or drug-like compounds and bisVCap 
were ground in the desired ratio, heated until all of the sample had melted then cooled back to 
room temperature and analyzed by polarized light microscopy. Carbamazepine, carisoprodol, 
isoniazid and ROY all showed no visible crystallization at a 2:1 drug:bisVCap molar ratio. 
Carisoprodol also did not show any visible crystallization at a 3:1 carisoprodol:bisVCap ratio. At 
3:1 drug:bisVCap ratio carbamazepine, isoniazid and ROY all formed crystals overnight and 
carisoprodol formed crystals overnight from a 4:1 ratio. Heat-cool-heat DSC experiments were 
performed for the ratios which did not form crystals in the hot stage microscope experiments. 
Similar to the 1:1 ratios, no recrystallization event or melt during the second heating cycle is 
present in the DSC plots for 3:1 carisoprodol:bisVCap, 2:1 carbamazepine:bisVCap, 2:1 
isoniazid:bisVCap or 2:1 ROY:bisVCap. This suggests that bisVCap is still an effective 
crystallization inhibitor at these ratios.  
Coamorphous preparations were also examined by XRPD. The amorphous samples were 
prepared by melting the two components together and allowing the samples to cool to room 
temperature for 18 hours. Carbamazepine:bisVCap 2:1 and 1:1 and carisoprodol:bisVCap 3:1, 
2:1 and 1:1 showed no Bragg peaks in the powder patterns, Figure , consistent with the formation 
of a coamorphous phase. The 1:1 ratio of ROY:bisVCap also proved amorphous by X-ray 
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diffraction, however the 2:1 ROY:bisVCap sample, while largely amorphous, exhibited some 
small Bragg peaks implying the beginning of crystallization of the API. 
 
Figure 4. XRPD diffractograms of a) carbamazepine with bisVCap in 1:1 and 2:1 molar ratios, 
b) carisoprodol with bisVCap in 1:1 and 2:1 molar ratios, c) isoniazid with bisVCap in 1:1 and 
2:1 molar ratios and d) ROY with bisVCap in 1:1 and 2:1 molar ratios. 
Neither isoniazid:bisVCap 2:1 or isoniazid:bisVCap 1:1 proved to be amorphous by XRPD. 
Comparison to powder patterns calculated from the literature crystal structures of isoniazid
47
 and 
bisVCap
48
 shows the material to be a mixture of the two known materials (supporting 
information, Figure S6). While the observation of crystalline material by XRPD is not consistent 
with the optical microscopy and DSC data, and it is likely that the crystallization of this mixture 
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is highly nucleation dependent and hence varies from sample-to-sample. After four weeks of 
being stored at room temperature, all samples except for 1:1 carisoprodol:bisVCap showed some 
evidence for crystallinity in their XRPD diffractograms, showing that over time they slowly 
revert to the more thermodynamically stable crystalline forms. The coamorphous form of 1:1 
carisprodol:bisVCap is stable over the course of a month and hence is very promising for drug 
formulation. In contrast, carisoprodol alone had fully crystallised after two weeks. 
IR spectra were recorded of carisoprodol, carbamazepine, isoniazid, ROY and bisVCap, 
as well as the 1:1, 2:1 and for carisoprodol 3:1 drug:bisVCap mixtures ground and co-melted. 
Simple grinding at room temperature of all four compounds with bisVCap did not result in any 
significant changes in the IR spectra, with the spectra being a simple superposition of those of 
the isolated components. Upon melting and cooling there are observable changes for 
carbamazepine, carisoprodol and isoniazid. For carisoprodol, Figure 5, when the sample is 
melted and cooled the carbonyl peaks of bisVCap at 1622 cm
-1 
and 1640 cm
-1
 become much 
broader and less well-defined, an observation consistent with the formation of amorphous 
material.
35, 49-51
 The carbonyl peak for the carisoprodol broadens and also shifts from 1690 cm
-1
 
to 1708 cm
-1
. This suggests that the carbonyl bonds are becoming stronger so less involved in 
any intermolecular bonding. The bands between 3475 – 3180 cm-1 which are associated with the 
N-H stretches of the carbamate groups, become a single broad peak in the spectrum of the cooled 
sample after melting, where in pure carisoprodol there were four sharp, distinct peaks. Upon 
increasing the ratio of carisoprodol:bisVCap from 1:1 to 2:1 to 3:1 there is no significant change 
in the position of any of the bands. The changes in the IR spectra of the co-melted carisoprodol-
bisVCap mixtures imply that there are changes in the local environment of the carisoprodol 
molecules which affect its crystallization, Figure 5. 
 17 
 
Figure 5. IR spectra of bisVCap, carisoprodol and a 1:1 molar ratio of carisoprodol:bisVCap 
ground and melted. 
Similarly, both carbamazepine and isoniazid show a large degree of broadening of the carbonyl 
peaks in the spectra of the cooled samples after melting while there is no change in the co-
ground sample. The spectra of cooled melts of samples of carbamazepine:bisVCap and 
isoniazid:bisVCap showed no change between the 1:1 and 2:1 ratios. On the other hand, ROY 
exhibits no change in peaks in the IR spectra in the ground or melted samples at either a 1:1 or 
2:1 ROY:bisVCap ratio. Even when melted and cooled, the spectrum for ROY/bisVCap is a 
mixture of the bisVCap and ROY spectra, with no shifts in the peaks of interest. This suggests 
that unlike carbamazepine, carisoprodol and isoniazid, which see significant changes to the local 
environment, the stabilization of the amorphous form in ROY/bisVCap does not arise from local 
intermolecular interactions. 
 A significant issue with PVP as an amorphous stabilizer is its hygroscopicity.
32
 Dynamic 
vapor sorption (DVS) has been used to compare the water uptake of bisVCap with PVP.
52
 The 
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DVS plot for crystalline bisVCap (Figure a), shows a mass increase of 0.35 % up to 90 % 
relative humidity. Amorphous bisVCap (Figure b), shows a larger mass increase of 1.2 % over 
the same range, however this small increase in mass and lack of hysteresis in the DVS plot 
suggest that both crystalline and amorphous bisVCap are not significantly hygroscopic. This data 
compares favorably with the roughly 40% increase in mass at 80% RH of PVP. Hence, unlike 
PVP, bisVCap is not hygroscopic may be a desirable amorphous stabilizer that is potentially less 
susceptible to absorption of atmospheric moisture.  
  
Figure 6. DVS data for a) crystalline bisVCap and b) amorphous bisVCap. 
Conclusion 
 
In conclusion, bisVCap appears to be a suitable small-molecule coamorphous phase former for a 
range of drugs and drug-like compounds, in some cases even at high drug-to-coformer ratio. 
Carisoprodol in particular showed promise, with a low loading of bisVCap and a long shelf life. 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0 50
P
e
rc
e
n
ta
ge
 m
as
s 
ch
an
ge
 /
 w
t%
 
Relative humidity / %RH 
first increase
first decrease
second increase
second decrease
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 50
P
e
rc
e
n
ta
ge
 m
as
s 
ch
an
ge
 /
 %
 
Relative humidity / %RH 
first increase
first decrease
second increase
second decrease
a) b) 
 19 
BisVCap is also much less hygroscopic than PVP. The concept of adapting small-molecule 
analogs of known polymeric dispersions as coformers for coamorphous phases is a potentially 
interesting avenue for future work. 
Experimental 
 
Differential scanning calorimetry  
Differential scanning calorimetry scans were recorded in standard mode on a TA Q2000 using 
standard aluminum pans containing 3 – 12 mg of sample. The heat/cool/heat cycles began with a 
heating cycle at a rate of 10 °C min
-1
, then cooling cycle at 10 °C min
-1
 and finally a second 
heating cycle at 10 °C min
-1
. 
Dynamic vapor sorption 
DVS was performed using an SMS DVS-1 with a 10 %RH step between humidity values with 
equilibrium achieved at 0.01% weight change before moving to the next step. Methods began at 
the humidity of the room at ambient which was measured by a Rotronic A/H hygrometer. The 
humidity was then increased to 90%RH before cycling to 0%RH, to 90%RH, to 0%RH. Samples 
weighing between 5-20mg were used. 
Hot stage microscopy 
A Linkam LTS420 heating stage attached to an Olympus XC50 microscope was used to heat the 
samples. Samples were placed on a glass microscope slide with a thin glass cover slide. For the 
amorphous material screening compounds were ground together in various drug to coformer 
ratio using 0.05 g of coformer in each case and heated at 30 °C min
-1
 until the all of the sample 
had melted. Samples were then removed from the hot stage and allowed to cool. BisVCap was 
ground in 1:1 molar mixture with carbamazepine, carisoprodol, isoniazid and ROY. The 
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carbamazepine/bisVCap sample was heated from room temperature to 170 °C at a rate of 10 °C 
min
-1
, cooled at 1 °C min
-1 
to -40 °C, then heated at 10 °C min
-1
 to 165 °C min
-1
. The 
carisoprodol/bisVCap sample was heated from room temperature to 150 °C at a rate of 10 °C 
min
-1
, cooled at 1 °C min
-1 
to -75°C, then heated at 10 °C min
-1 
to 145 °C min
-1
. The 
isoniazid/bisVCap sample was heated from room temperature to 175 °C at a rate of 10 °C min
-1
, 
cooled at 1 °C min
-1 
to -100 °C, then heated at 10 °C min
-1 
to 125 °C min
-1
. The ROY/bisVCap 
sample was heated from room temperature to 150 °C at a rate of 10 °C min
-1
, cooled at 1 °C min
-
1 
to -90 °C, then heated at 10 °C min
-1 
to 155 °C. 
Infrared spectroscopy 
Experiments were performed on a Perkin Elmer FTIR spectrum 100 with an attenuated total 
reflectance (ATR) attachment. Data were recorded at a resolution of 2 cm
-1
 for 16 scans over the 
range 4000 – 600 cm-1. Samples were run by placing on the ATR crystal and applying pressure 
using the side arm. Spectral analysis was performed using SpekWin32. Ground samples were 
prepared by grinding together in the desired ratio of the two components using a mortar and 
pestle for one minute. Melted samples were prepared by grinding together in the desired ratio of 
the two components using a mortar and pestle for one minute before placing the ground material 
into 5 mL glass vial with a plastic screw lid. After the lid was secured the sample was heated 
above the melting point of the highest melting component until everything had melted using a 
stirrer hotplate and appropriate heating block. 
Crystallographic analysis  
X-ray powder diffraction patterns were recorded on a PANalytical Empyrean diffractometer 
using Cu Kα radiation (λ = 1.54 Å), tube voltage of 40 kV and 40 mA current. Intensities were 
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measured from 2° to 40° 2θ. Soller silts and an incident beam divergent slit of 
1
8
°, anti-scatter slit 
of 
1
4
° and diffracted beam anti-scatter slit of 7.5 mm. 
Materials and Methods 
Compounds 3 – 7 were prepared according to previously published procedures.52 PVP K12 and 
PVCap were supplied by Ashland Inc. Compound 8 was prepared as detailed below. 
N-vinyl(caprolactam) (2.0 g, 14.4 mmol) and hydroxyethylpyrrolidone (1.9 g, 14.4 mmol) 
were added to cyclohexane (10 cm
3
) in a two neck round bottom flask with a reflux condenser. 
0.5 cm
3
 of TFA was added and the mixture was heated at 40 °C for 6 hours. The solvent was 
removed under vacuum to leave an orange oil. Unreacted N-vinyl(caprolactam) was removed 
using an alumina column with 75:25 diethyl ether : methanol mobile phase. The solvent was 
removed under vacuum and the resulting yellow oil was left in a vacuum desiccator under 
vacuum overnight to remove any remaining solvent residues. 
1
H NMR (400 MHz, D2O) δ 5.58 
(q, J = 6.0 Hz, 1H), 3.54 – 3.37 (m, 6H), 3.37 – 3.28 (m, 1H), 3.23-3.15 (m, 1H) 2.63 – 2.42 (m, 
2H), 2.35 (t, J = 8.1 Hz, 2H), 2.00 (q, J = 7.5 Hz, 2 H) 1.79 – 1.46 (m, 6H), 1.23 (d, J = 6.0 Hz, 
3H). 
13
C{
1
H} NMR (101 MHz, CDCl3) δ 176.70, 175.18, 79.33, 65.37, 48.34, 42.36, 40.96, 
37.61, 30.82, 29.98, 29.26, 23.48, 19.19, 18.05. ESI-MS m/z 559 (2M+H
+
, 100%), 269 (M+H
+
, 
58), 140 (45), 130 (36), 65 (14). 
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This work examines the use of small-molecule bis(lactams) analogous to poylvinylpyrrolidone as 
stabilizers of coamorphous pharmaceutical phases. 
 
 
 
 
